Thymosins in Health and Disease

Enrico Garaci, MD is Professor in the Department of Experimental Medicine and Biochemical Sciences at the University of Rome 'Tor Vergata'. Mr. Garaci is a leading clinical and basic researcher in the fields of host-pathogen interactions and immunotherapy of cancer and hepatitis infections. Allan L. Goldstein is Emeritus Professor in the Department of Biochemistry and Molecular Medicine at The George Washington University School of Medicine. He chaired the department from 1978 until March 2009 and was awarded Emeritus status in 2013.

• Part I: Thymosins: Structure and Design, Isoforms, Genomics, Multifunctionality:. 1. Contributions from all over: widely-distributed residues in thymosin β4 affect the kinetics and stability of actin binding: Daniel Safer.2. The β-thymosin engima: Helen L. Yin.3. The interaction of the C-terminal half of thymosin β4 with actin: Robert C. Robinson.4. Evolution of the actin-sequestering function in β-thymosins and modular β-thymosin repeat proteins: Marie-France Carlier.5. Thymosin β4: actin regulation and more: Elena G. Yarmola.6. The thymosin fold among cytoskeletal proteins: multifunctionality and structure: Roberto Dominguez.Part II: Wound Healing, Inflammation, and Fibrosis:.7. Unexpected findings in mice overexpressing thymosin β4: Hynda Kleinman.8. Adhesive and proteolytic phenotype of migrating endothelial cells induced by thymosin β4: Czeslow S. Cierniewski.9. Thymosin β4 and the eye: I can see clearly now the pain is gone: Gabe Sosne.10. In vivo detection of thymosins via mass spectrometric proteomics an ultrafiltration sampling: the role of in vivo secreted-thymosins in skin biology: Chun-Ming (Eric) Huang.11. Airway disease and sputum: the role of DNA and actin polymers: Bruce Rubin.12. Liver cirrhosis: a reversible process?: Marcos Rojkind.Part III: Cardiovascular Protection, Neuroplasticity, Stem Cells Repair, and Regeneration:.13. Cardiac protection and angiogenesis induced by thymosin β4: Deepak Srivistava.14. Thymosin β4: the potential for neovascular therapy in the injured adult heart: Paul R. Riley.15. Post-translational regulation of β-thymosin repeat protein: contribution to intrinsic cellular excitability: Terry Crow.16. Prothymosin α in relation to chromatin decondensation and the role of β-thymosins in synaptic plasticity: Jaime Gomez-Marquez.17. Thymosin β4 as a protective agent in the nervous system and the effects of its overexpression/ablation in neuronal and tumoral stem cells: Daniela Merlo.18. Emerging multipotent roles of thymosin β in the development and regeneration of the nervous system: Woong Sun.Part IV: Immunopharmocology, Pharmacogenomics, and Combination Therapies:.19. Thymosin alpha 1 from bench to bedside: Enrico Garaci.20. Immunopharmacology of thymosin α1: Paul Naylor.21. IRX-3: A novel biologic to reverse immune suppression: John Hadden.22. Clinical experiences with thimosins in influenza: William Ershler.23. IFN-α and novel strategies of combination therapy of cancer: Filippo Belardelli.24. Combination Trials with thymosin alpha 1 in hepatitis B and C: Guido Rasi.Part V: Molecular Markers, Signaling, and Diagnostics for Cancer and Infectious Diseases:.25. Thymosin α1 as a chemopreventive agent in breast and lung cancer: Terry Moody.26. Characterization of a peptide component of thymosin fraction-5 manifesting cytostatic properties in HL-60 human promyelocytic leukemia cells: Brian Spangelo.27. Cellular distribution of thymosin β4 in tumors: Lars-Inge Larsson.28. Anti-HIV-1 activity of both thymosin β4 and prothymosin α: Arevik Mosoian.29. Thymosin α1: an endogenous regulator of inflammation and tolerance in antimicrobial immunity and autoimmunity: Luigina Romani.30. Activation of signal pathways by thymosin α1: Wen-ming Chu.Part VI: Clinical Applications of Thymosin a1 and Thymosin b4:.31. Issues in pharmaceutical development of thymosin α1 from preclinical studies through marketing: Cynthia Tuthill.32. Clinical experience with the role of thymosin alpha 1 in hepatitis B and C: Vinod K. Rustgi.33. European Phase III, Randomized, Double Blind, Multicenter Study of Triple Therapy with Thymosin alpha 1 plus Pegylated Interferon alpha-2a plus Ribavirin in Non Responder Patients with Chronic Hepatitis C. Study Design and Preliminary Safety Data: Mario Rizzetto.34. Development of Thymosin β4 for Ischemic Heart Disease: David Crockford.35. β-thymosin and venous ulcers: clinical remarks on a European perspective, randomised study on safety, tolerabiilty, and enhancement on healing: Giorgio Guarnera.36. Myocardial infarction markers in patients with acute limb ischaemia: Piotr Gutowski.37. Thymosin β4 and epidermolysis bullosa: Jo-David Fine.38. Chronic Cutaneous Wound Treatment: Pressure Ulcers – A Role for Thymosin β4: Mike Godschalk